Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » ProtoKinetix AAGP® in Phase 3 Retinal Replacement Program..

 - UBBFriend: Email this page to someone!    
Author Topic: ProtoKinetix AAGP® in Phase 3 Retinal Replacement Program..
jackbequick
Member


Rate Member
Icon 14 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
***PKTX..PR News Release..
ProtoKinetix AAGP® in Phase 3 Retinal Replacement Program
Press Release |04/23/2019
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) updates its stockholders regarding phase 3 of testing using AAGP® in retinal cell replacement therapy at the University of British Columbia.

The study is now using 2-animal models and a significantly larger number of animals in both control and AAGP® treated groups for a longer time frame. Until this study, the longest a group was tested for was 4-weeks. In this study, the lab currently has animals at the 3-month mark. All animals are reported to be healthy and behaving normally. Early results from this intensive program are expected to be presented to the Company by the end of July 2019. This study is being conducted to test whether AAGP® treated cells continue to develop into retinal cells. If successful, this may potentially lead towards the restoration of vision in humans.

This procedure could become a critical approach for the treatment of retinal diseases including Age-Related Macular Degeneration (AMD). The study is being conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia.

Dr. Gregory-Evans Bio

Dr. Gregory-Evans Video

The global ophthalmic therapeutics/drug market is expected to reach USD $35.7 billion by 2025, according to a new report by Grand View Research, Inc.

The retinal replacement program is just one of several ongoing studies involving our AAGP® molecule. Other ongoing studies are for:

Type one diabetes, islet cell transplants. Currently in clinical trials.
Cord Blood Stem Cell Storage and Recovery.
Cord Blood Stem Cell Transplantation and Engraftment.
Protection and repair of cardiac damage due to toxicity or heart attacks.
Whole organ preservation extending time for human organ transplants.

Posts: 172 | From: Florida | Registered: Dec 2009  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2019 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share